Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 145,807 shares, a growth of 80.4% from the June 30th total of 80,824 shares. Based on an average daily trading volume, of 139,949 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.9% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several brokerages have commented on ALLR. Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Friday, July 17th. Ascendiant Capital Markets upped their target price on Allarity Therapeutics from $9.75 to $10.25 and gave the stock a “buy” rating in a report on Monday, June 8th. Finally, Wall Street Zen raised Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Allarity Therapeutics presently has a consensus rating of “Hold” and an average price target of $10.25.

Allarity Therapeutics Trading Down 1.6%

Shares of ALLR stock opened at $1.21 on Friday. The company’s fifty day moving average price is $1.37 and its 200-day moving average price is $1.25. The stock has a market cap of $19.25 million, a PE ratio of -1.68 and a beta of 0.53. Allarity Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.35.

Allarity Therapeutics (NASDAQ:ALLR) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.05. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. On average, sell-side analysts forecast that Allarity Therapeutics will post -0.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Allarity Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in shares of Allarity Therapeutics during the second quarter valued at approximately $27,000. XTX Topco Ltd purchased a new stake in shares of Allarity Therapeutics in the 4th quarter worth approximately $36,000. Geode Capital Management LLC grew its stake in shares of Allarity Therapeutics by 49.3% in the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after buying an additional 16,729 shares during the last quarter. Citadel Advisors LLC bought a new position in Allarity Therapeutics during the 3rd quarter valued at approximately $149,000. Finally, Capital Advisors Inc. OK bought a new position in Allarity Therapeutics during the 4th quarter valued at approximately $108,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.